38 results about "Therapy related" patented technology

A method of treating a metabolic condition in a patient, comprising:determining a target non-immediate effect of a therapy relating to treatment of a metabolic condition; andapplying an electric field to an abdominal cavity of the patient in a manner designed to at least approach said target.

The invention relates to remote controlled blood cleaning of a patient (P). A dialysis unit (110) treats the patient's (P) blood in accordance with a prescribed therapy. The dialysis unit (110) has a bi-directional wireless interface (110W-120W) towards a gateway unit (120), which is further connected (125) to a remote host (140) via at least one interconnecting network (130). Thus, therapy related parameters (Dbp, Dr, dh, Dw) can be transmitted from the dialysis unit (110) to the remote host (140). It is also rendered possible for the remote host (140) to transmit control data (Dctr1) to the dialysis unit (110), the control data (Dctr1) influencing the prescribed therapy being, or to be, executed by the dialysis unit (1 10).

Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

A method of treating a metabolic condition in a patient, comprising:determining a target non-immediate effect of a therapy relating to treatment of a metabolic condition; andapplying an electric field to an abdominal cavity of the patient in a manner designed to at least approach said target.

The invention discloses an in-vivo wireless communication device based on a vascular stent and a wireless communication system. The in-vivo wireless communication device comprises the vascular stent and a trigger circuit mounted on the vascular stent, the trigger circuit is used for acquiring health condition data related to vascular diseases and / or providing in-vivo therapy related to the vascular diseases, an output of the trigger circuit is fed to the vascular stent, the vascular stent serves as an antenna to transmit wireless signals outwards, and the vascular stent further serves as the antenna to receive wireless signals in vitro and transmit the wireless signals to the trigger circuit. A special antenna structure does not need to be arranged in a blood vessel, the in-vivo wireless communication device is small in size, and the blood vessel can be monitored and treated in real time at low cost.

Disclosed are methods to identify an agent which may modulate resistance to HIV-1-mediated disease, comprising contacting at least one agent to be tested with a cell comprising human ICAM-1, and detecting the cell's resistance to HIV-1 viral replication, propagation, or function, wherein an agent is identified by its ability to increase the cell's resistance to HIV-1 viral replication, propagation, or function. Also disclosed are human mutant ICAM-1 polypeptides and methods to treat HIV-1 viral replication, propagation, or function in a human subject by ICAM-1 gene therapy relating to one or more of the following 10 mutations to human ICAM-1: L18Q, K29D, P45G, R49W, E171Q, wherein the mutant ICAM-1 is otherwise identical to human ICAM-1.

The present invention relates to inhibition of viruses, e.g., HIV using oxindoles and compounds related to oxindoles. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

The present invention concerns diagnosing and / or prognosticating cancer in an individual and / or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.

The invention discloses a system capable of simultaneously detecting tumor targeting therapy related target spots and immunotherapy related TMB and MSI. The system comprises a library preparation reagent, a probe, a hybridization capture reagent and a data analysis system, wherein the library preparation reagent, the probe and the hybridization capture reagent can be used for sequencing a library,and the data analysis system can analyze results including data quality control information and statistical information, mutation site information and TMB values.

The invention relates to MIT biomarkers and methods using the same. Provided are therapies related to the treatment of pathological conditions, such as cancer.

The invention belongs to the technical field of medical imaging, and specifically relates to a tumor-targeting polypeptide probe and application of the probe in tumor imaging. The invention relates to the tumor-targeting polypeptide probe. The general formula of the polypeptide probe is R-X-YW7, the YW7 is a polypeptide specifically targeting ANXA2 in vivo, and the sequence is YWRGVYN; and X is a linker, R is a signal unit, and X and R are covalently connected. The polypeptide probe is applied to preparation of a tumor diagnosis reagent, a tumor imaging reagent, a tumor operation guiding agent and / or a tumor active targeted therapy related drug tracer. Experiments prove that the tumor-targeting polypeptide probe provided by the invention has strong specificity and high sensitivity, and through a nude mouse subcutaneous pancreatic cancer model, a nude mouse subcutaneous glioma model and a nude mouse in-situ glioma model which are cultured in sequence, the polypeptide probe can be specifically absorbed by glioma, and quickly accumulates in tumor cells or tumor tissues within 2 hours; and compared with a control group, the tumor-targeting polypeptide has a remarkable tumor targeting advantage, and is clinically used for tumor diagnosis and treatment.

The present invention, fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein / gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is controlled by immunological assays based on reactive antibodies against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques as ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease, in cases in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamin detoxification.

The subject invention concerns new methods which make it possible, for the first time, to grow functional islet-producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) in in vitro cultures. The subject invention also concerns the use of the in vitro grown IPSCs, IPCs and / or IdIs for implantation into a mammal for in vivo therapy of diabetes. The subject invention further concerns a process of using the implanted cells for growing a pancreas-like structure in vivo that has the same functional, morphological and histological characteristics as those observed in normal pancreatic endocrine tissue. The ability to grow these cells in vitro and pancreas-like structures in vivo opens up important new avenues for research and therapy relating to diabetes.

A computer-implemented method is provided for taking one or more actions relating to therapy, the method comprising: obtaining data comprising audio data relating to a therapy session between a therapist and one or more patients; extracting text data from the audio data to form a transcript; dividing the transcript into a plurality of utterances; using at least a first part of a deep learning model to assign a semantic representation to each of the plurality of utterances to produce a plurality of assigned utterances; compiling the plurality of assigned utterances to form a representation of the therapy session; using at least a second part of a deep learning model, and an input comprising the representation of the therapy session, to obtain an output predicting a characteristic of the therapist, and / or the therapy, and / or the one or more patient; and causing the system to take one or more actions relating to the therapy, wherein the one or more actions are selected based on the output meeting one or more predetermined criterion.

Methods and systems for providing therapy related data management are provided. The subject systems include one or more device components, and at least one memory storage unit and at least one data storage unit associated with such one or more device components. The device components may include one or more of an analyte monitoring system, a fluid delivery device and a remote terminal. The subject methods include use of the subject systems to optimize treatment of a patient.

Methods and systems for improving nerve stimulation are disclosed which relate to shaping characteristics of the stimulation field such as by using different geometries and locations of stimulation. In embodiments, systems and methods are provided to improve selective modulation of specific targeted neural substrate, while minimizing the activation of adjacent non-targeted nervous tissue. While aspects of the disclosed technologies can be applied to any part of the central and peripheral nervous systems for treatment various disorders and providing symptom relief to provide for therapy related to pelvic floor disorders such as overactive bladder

The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding NP95, which is involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of NP95; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

The present invention relates to regulation of the cell cycle. More particularly, the present invention is directed to nucleic acids encoding components of the ubiquitin ligation pathway, e.g., ubiquitin and ubiquitin-like molecules, E1, E2, and E3 proteins and their substrates, which are involved in modulation of cell cycle arrest. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle arrest via modulation of the ubiquitin ligation pathway; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.

The present invention relates to regulation of adult lifespan in eukaryotes. More particularly, the present invention is directed to methods of assaying for genes, gene products, and genes in pathways controlled by such genes and gene products, using RNAi and microarray analysis, that regulate lifespan (e.g., extend or truncate adult lifespan) in eukaryotes such as invertebrates (e.g., C. elegans), plants, and mammals, e.g., humans. For example, the present invention is directed to genes encoding components of the mitochondrial respiratory chain and genes encoding glycolysis enzymes, which are involved in lifespan regulation, and genes and gene products in pathways controlled by such genes. Other genes and gene products identified as regulating aging and aging pathways include a gene encoding a GTPase; a transcriptional activator; novel genes: llw-1, llw-2, llw-3, and llw-4; genes encoding cytochrome P450 proteins (involved in steroid biosynthesis); a melatonin synthesis gene; genes encoding insulin and insulin-like peptides; genes encoding heat shock factors; genes encoding catalases; stress-response genes; and metabolic genes. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, antisense nucleic acids, and ribozymes, that regulate, e.g., enhance, adult lifespan via modulation of aging associated proteins; as well as to the use of expression profiles, markers, and compositions in diagnosis and therapy related to lifespan extension, life expectancy, and aging. The present invention also relates to gene therapy involving lifespan associated genes.

The invention discloses a lymph purification therapeutic apparatus provided with a thoracic duct lymph drainage tube. An end of the thoracic duct lymph drainage tube includes three branches that are connected with a drainage tube pressure sensitive cuff, a drive pump and a lymph purifier outlet; the driving pump is connected with a suction jar that is connected with a lymph purifier inlet; the lymph purifier is connected with a displacement liquid feeder. This apparatus drains all lymph out from the intestinal system, thus avoiding blood entry; low disturbance is caused to the internal environment; the anticoagulation problem is weakened, and the risk of bleeding and clotting is greatly reduced; a therapeutic dose is low; a treatment period is shortened; the influence of bedside blood purification therapy on drug removal can be reduced, and high efficient drug concentration in blood is maintained, thus improving therapeutic effect of drugs such as antibiotics, reducing dosage of the antibiotics, reducing drug resistance and lowering drug therapy related costs.

The present invention pertains to a device and corresponding method for determining information relating to the treatment of a patient, preferably relating to a patient having a respiratory disorder. The device comprises a fluid channel configured to be in fluid communication with a medical gas source at a first end and with a patient interface at a second end, a sensor arrangement having at least a first sensor for measuring a value of a first flow parameter in the channel and a second sensor for measuring a value of a second flow parameter in the channel, wherein the first sensor and the second sensor are spaced apart from each other along a longitudinal axis of the channel, and a control unit in communication with the first sensor and the second sensor. The control unit determines flow direction of a medical gas in the channel based on sensor measurements.

A computer-implemented method is provided for taking one or more action relating to therapy.The method comprising: receiving text data relating to a therapy session between a therapist and a patient;dividing the text data into a plurality of utterances; assigning a semantic representation to each of the plurality of utterances to produce a plurality of assigned utterances; aggregating the plurality of assigned utterances to form a representation of the therapy session; providing an output prediction, based on the representation of the therapy session and optionally one or more further input,of one or more characteristic of at least one of the patient, the therapist and the therapy; taking one or more action relating to the therapy, wherein the one or more action is selected based on theoutput prediction meeting a predetermined criterion.